dehydroepiandrosterone 100 and

Small molecule

dehydroepiandrosterone 100 and is one of 4 small molecule programs targeting Myotonic Dystrophy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic DystrophyActive, not recruiting

Myotonic DystrophyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Myotonic Dystrophy

#DrugCompanyPhaseTrials

Mexitil

Boehringer Ingelheim

Approved

1 2

Tideglusib

AAMO Pharma Limited

Phase 3

4 3

VX-670

Vertex Pharmaceuticals

Phase 2

1 4

dehydroepiandrosterone 100 and

UUniversity of Versailles

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myotonic Dystrophy1 trial

Efficacy and Safety of DHEA for Myotonic Dystrophy

Completed·UUniversity of Versailles·Phase 2/3·NCT00167609·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dehydroepiandrosterone 100 and. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dehydroepiandrosterone 100 and compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dehydroepiandrosterone 100 and. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Versailles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Versailles

dehydroepiandrosterone 100 and

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myotonic Dystrophy1 trial

References

Drug Info

Quick Facts

Related News